Neuland Laboratories profit and loss

Latest FY26
Revenue
₹2,023cr+37.0% on FY25
EBITDA
₹574cr+77.7% on FY25
Net profit
₹364cr+39.9% on FY25
EPS
₹283.71+39.9% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2,3722,0231,4771,5591,191
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
30.830.220.512.59.7
2,4032,0531,4971,5711,201
Expenses
887820575632488
−24.1−64.312.8−55.1−9.5
374341272257202
26.323.98.314.013.1
98.191.765.559.752.8
372352294262239
1,7331,5641,2271,170985
763574323463272
665483258403219
Profit
669489270401216
0.00.076.40.00.0
669489346401216
17512973.899.750.4
−4.0−4.012.51.71.8
17112586.210152.2
498364260300164
498364260300164
0.91.1−0.01.4−3.5
499365260301160
498364260300—
Per share
₹387.97₹283.71₹202.74₹233.89₹127.45
₹387.97₹283.71₹202.74₹233.89₹127.45
Other comprehensive income — detail
0.91.1−0.0——
—0.5−0.31.4−3.9
—0.1−0.1——
—0.70.2——
0.10.00.0——
———0.0−0.4
499365260300—
Per share — as-filed variants
₹387.97₹283.71₹202.74₹233.89₹127.45
₹387.97₹283.71₹202.74₹233.89₹127.45
Derived — gross profit (revenue − materials − purchases − Δ inventories)
1,5091,267889981713
63.6%62.7%60.2%63.0%59.9%
Adjusted (ex-exceptional items) — derived
669489270401216
0.00.076.40.00.0
498364203300164
₹387.97₹283.71₹158.01₹233.89₹127.45
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NEULANDLAB₹19,970.00

Neuland Laboratories Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersDIVISLABLAURUSLABSNHNATCOPHARMLALPATHLABSAILIFECOHANCEASTERDMMcap ₹25,762 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,191.21,558.61,476.82,023.02,371.8
Other Income9.712.520.530.230.8
Total Income1,200.91,571.11,497.32,053.22,402.6
Expenses
+ Cost of Materials Consumed487.7632.4574.8819.8887.1
+ Changes in Inventories-9.5-55.112.8-64.3-24.1
+ Employee Benefit Expense201.8257.1272.0341.1374.1
+ Finance Costs13.114.08.323.926.3
+ Depreciation & Amortisation52.859.765.591.798.1
+ Other Expenses239.3261.6293.9351.8371.8
Total Expenses985.21,169.71,227.41,564.21,733.4
EBITDA271.8462.6323.3574.5762.9
EBIT219.1402.9257.7482.8664.8
Profit
PBT before Exceptional Items215.7401.4269.9489.0669.3
+ Exceptional Items0.00.076.40.00.0
Pretax Income215.7401.4346.3489.0669.3
+ Current Tax50.499.773.8129.0175.5
+ Deferred Tax1.81.712.5-4.0-4.0
Tax Expense52.2101.486.2125.0171.5
Net Income163.5300.1260.1364.0497.8
+ Net Income — Continuing Ops163.5300.1260.1364.0497.8
+ Other Comprehensive Income-3.51.4-0.01.10.9
Total Comprehensive Income160.0301.4260.1365.1498.6
Net Income to Common—300.1260.1364.0497.8
Per Share
Basic EPS127.45233.89202.74283.71387.97
Diluted EPS127.45233.89202.74283.71387.97
Other Comprehensive Income — detail
+ Other Comprehensive Income——-0.01.10.9
+ Items NOT to be Reclassified to P&L-3.91.4-0.30.5—
+ Tax on Items NOT to be Reclassified——-0.10.1—
+ Items to be Reclassified to P&L——0.20.7—
+ Tax on Items to be Reclassified——0.00.00.1
+ Tax on Items to be Reclassified — alt tag-0.40.0———
Comprehensive Income — Owners of Parent—300.1260.1365.1498.8
Per Share — as-filed variants
Basic EPS — Continuing Operations127.45233.89202.74283.71387.97
Diluted EPS — Continuing Operations127.45233.89202.74283.71387.97
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit713.0981.3889.21,267.51,508.8
Gross Margin %59.8562.9660.2162.6563.62
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)215.7401.4269.9489.0669.3
− Exceptional Items (reconciliation)0.00.076.40.00.0
Net Income Adj (tax-effected)163.5300.1202.7364.0497.8
EPS Adj127.45233.89158.01283.71387.97
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.00
Paid Up Equity Capital12.912.912.912.912.9
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.